Substance / Medication

Triamterene

Overview

Active Ingredient
triamterene
RxNorm CUI
10763

Indications

This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. Triamterene and hydrochlorothiazide tablets are indicated for the tre

Labeler: NuCare Pharmaceuticals,Inc.Updated: 2026-02-20T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial.
Taban-Sadeghi Mohammadreza, Khani Elnaz, Khezripour Kimia et al. · J Clin Pharmacol · 2023
PMID: 37493211RCT
Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations.
Hamidi Mehrdad, Shahbazi Mohammad-Ali, Azimi Kourosh · Regul Toxicol Pharmacol · 2011
PMID: 21193005RCT
Validated spectroscopic methods for the estimation of triamterene in bulk powder and capsule form via derivatization reactions.
Ibrahim Fawzia A, Fouad Manal M, Rashed Noha S et al. · Luminescence · 2018
PMID: 30362232Observational
Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension.
Tu Wanzhu, Decker Brian S, He Zangdong et al. · J Gen Intern Med · 2016
PMID: 26194642ObservationalFull text (PMC)
Bioavailability study of triamterene and xipamide using urinary pharmacokinetic data following single oral dose of each drug or their combination.
Maher Hadir M, Youssef Rasha M, El-Kimary Eman I et al. · J Pharm Biomed Anal · 2012
PMID: 22197154Observational
Spectrophotometric and spectrodensitometric determination of triamterene and xipamide in pure form and in pharmaceutical formulation.
Wagieh Nour E, Abbas Samah S, Abdelkawy M et al. · Drug Test Anal · 2010
PMID: 20878892Observational
Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
Fuhr U, Kober S, Zaigler M et al. · Int J Clin Pharmacol Ther · 2005
PMID: 16035375Observational
Multicommuted flow-through fluorescence optosensor for determination of furosemide and triamterene.
Llorent-Martínez E J, Ortega-Barrales P, Molina-Díaz A · Anal Bioanal Chem · 2005
PMID: 16211379Observational
Determination of triamterene and its main metabolite hydroxytriamterene sulfate in human urine by capillary electrophoresis using ultraviolet absorbance and laser-induced fluorescence detection.
Horstkötter Christian, Kober Susan, Spahn-Langguth Hildegard et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2002
PMID: 11936683Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Triamterene (substance)
SNOMED CT
387053007
UMLS CUI
C0040869
RxNorm CUI
10763
Labeler
NuCare Pharmaceuticals,Inc.

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.